

# The Nikkan Yakugyo

Dairly pharmaceutical news 30<sup>th</sup>. Aug.2019by Jiho,Inc : Tokyo JAPAN

## **NASH (Non Alcoholic Steatohepatitis) treatment with drug repositioning by Polaprezinc and Sodium selenite compound**

Medico-Consil Co.,LTD(M·C), a drug discovery start-up, is working on a study that the combination of (zinc) Polaprezinc and (selenium) Sodium selenite can be NASH treatment.

In( STAM <sup>TM</sup>) NASH animal models, they has confirmed significant improvements in many items related to NASH and aim to develop the drug in partnership with pharmaceutical companies.

Polaprezinc(original drug:Promac®) has been used for more than 20 years as a gastric ulcer treatment. Sodium selenite is used for hyposelenemia as an injection.

In JAPAN, it was approved to be manufactured and sold in March 2019.

Mr.Kono(Sapporo Higashi Tokushukai Hospital), who collaborated with Mr.Kubota(M·C), administered Polaprezinc and Sodium selenite compound to NASH animal model and confirmed that liver fibrosis area, intrahepatic triglyceride and other related markers were significantly reduced.

In particular, NAS(NAFLD active score) changed by less than 2 and the tissue was improved to be non-NASH. Some of these results were presented by Mr. Kono at the Japanese Society of Gastroenterology in May 2019.

Mr.Kubota paid attention to the pharmacological action of Polaprezinc in the liver tissue. Mr. Kono clarified the liver fibrosis-suppressing effect of this drug discovered sodium selenite an ingredient that can obtain additive synergistic effects with Polaprezinc and as a result of research on NASH treatment with Polaprezinc and Sodium selenite compound, that compound showed an excellent improvement effect.

M·C has applied for application patents in Japan , China ,U.S.A and so on.

Mr.Kubota commented to the interview that "Polaprezinc and Sodium selenite have been tested for toxicity and safety has been confirmed, so the development of the formulation can now save time and money."Mr.Kubota said approval of Sodium selenite is a great opportunity and this is the opportunity to focus on clinical development.

This wrighting is translated a part of The Nikkan Yakugyo 30<sup>th</sup> Aug 2019 issue into English

3<sup>rd</sup> Sept 2019